Santen Pharmaceutical Co., Ltd.: Keratoconjunctivitis Sicca trials
The registry lists 13 Keratoconjunctivitis Sicca studies with Santen Pharmaceutical Co., Ltd. as lead sponsor. 0 are open to participants now and 3 have results posted.
Phase 1 2Phase 2 5Phase 3 3No phase 4(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- 3-year Study in Dry Eye Disease Patients With Severe Keratitis Receiving Ikervis® (1mg/mL Ciclosporin)CompletedNCT04144413Phase 3Results posted
- Phase III Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedNCT01240382Phase 3Results posted
- Late Phase II Confirmatory Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedNCT01189032Phase 2Results posted
- 3 Month Study of Cationorm Pro Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or KeratoconjunctivitisCompletedNCT04701086Not applicable
- 3 Month Study of Alocross Versus Vismed in Adults With Dry Eye Disease Related to Keratitis or KeratoconjunctivitisActive, not recruitingNCT04685109Not applicable
- Assessing Safety and Efficacy of DE-089 Ophthalmic Solution in Patients With Dry Eye DiseaseCompletedNCT03216096Phase 1
- A Randomized, Parallel-Group Comparison Study of Topical Corticosteroids in Dry Eye Patients With Sjögren SyndromeCompletedNCT02011776
- A Study Assessing the Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye PatientsCompletedNCT01468168Phase 2
- Safety and Efficacy Study of DE-110 Ophthalmic Suspension for the Treatment of Dry Eye DiseaseCompletedNCT01239069Phase 2
- Study Assessing Safety and Efficacy of DE-101 Ophthalmic Suspension in Dry Eye PatientsCompletedNCT01118754Phase 1/2
- Study of DE-089 Ophthalmic Solution in Patients With Dry EyeCompletedNCT01101984Not applicable
- A Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Subconjunctival Injection of Sirolimus in Patients With Dry Eye in the Controlled Adverse Environmental (CAE) ModelCompletedNCT00814944Phase 2
- Double-Masked Trial of NOVA22007 (Ciclosporin 0.1%) Versus Vehicle in Patients With Moderate to Severe Dry Eye SyndromeCompletedNCT00814515Phase 3